Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Sharman, J. P., Andorsky, D. J., Cohen, J. B., Barve, M. A., Ghia, P., Yin, M., Zinzani, P. L., Ujjani, C., Koh, Y., Izutsu, K., Lech-Maranda, E., Kherani, J., Tam, C., Sundaram, S., Nair, B., Tsai, D. E., Balbas, M., Mato, A. R., & Cheah, C. Y. (n.d.). p1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 991–992. http://access.bl.uk/ark:/81055/vdc_100159757373.0x00000c